By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Scancell, Ltd. 

P.O. Box 6457

Nottingham    NG5 1QA  United Kingdom
Phone: 44-0-115-962-8033 Fax: +44-0-115-962-8033



Company News
Scancell And Immunid Announce Collaboration To Predict SCIB1 Responders Using Immuntracker 7/30/2015 9:22:27 AM
Scancell Patient Recruitment Completed For SCIB1 Phase 1/2 Clinical Trial 7/9/2015 8:22:19 AM
ASCO15: Scancell Provides Positive Update On SCIB1 Data In Resected Melanoma Patients 6/2/2015 9:31:04 AM
Scancell To Provide Update On SCIB1 Data In Resected Melanoma Patients At 2015 ASCO Annual Meeting 5/18/2015 12:41:09 PM
Scancell To Provide Positive SCIB1 Phase 1/2 Clinical Trial Update During Corporate Presentations 12-15 January, San Francisco 1/12/2015 11:21:26 AM
Scancell Release: AGM Research And Development Update Highlights Progress In Both SCIB1 Clinical Trial And Moditope® Platform 10/14/2014 10:35:20 AM
Scancell To Present At Upcoming Scientific Conferences 9/12/2014 10:15:49 AM
Scancell Release: Final Results For The Year Ended 30 April 2014 9/4/2014 2:39:25 PM
Scancell Release: Synergy Of SCIB1 With Checkpoint Inhibitors 8/12/2014 12:42:52 PM
Scancell: DNA ImmunoBody Patent Granted In United States 6/6/2014 10:47:58 AM